Melatonin and celecoxib improve the outcomes in hamsters with experimental pancreatic cancer

Journal of Pineal Research

Volumn 49, Issue 3, 2010, Pages 264-270

  Padillo, Francisco J ^a   Ruiz Rabelo, Juan F ^b   Cruz, Adolfo ^b   Perea, María D ^b   Tasset, Inmaculada ^c   Montilla, Pedro ^c   Túnez, Isaac ^c   Muntané, Jordi ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

celecoxib; melatonin; oxidative stress; pancreatic cancer

Indexed keywords

CATALASE; CELECOXIB; GLUTATHIONE; GLUTATHIONE PEROXIDASE; LIPID PEROXIDE; MELATONIN; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; HAMSTER; HISTOPATHOLOGY; MALE; NONHUMAN; OXIDATIVE STRESS; PANCREAS CANCER; TREATMENT OUTCOME;

ANIMALS; ANTIOXIDANTS; CATALASE; CRICETINAE; CYCLOOXYGENASE 2 INHIBITORS; GLUTATHIONE; GLUTATHIONE PEROXIDASE; LIPID PEROXIDES; MELATONIN; MESOCRICETUS; OXIDATIVE STRESS; PANCREATIC NEOPLASMS; PYRAZOLES; SULFONAMIDES; SUPEROXIDE DISMUTASE;

EID: 77956330076     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2010.00791.x     Document Type: Article

References (50)

1. John L. Cameron. Current Surgical Therapy, 8th edn. Elsevier, Mosby, 2008.
2. Yeo CJ, Hruban RH, Conlon KC et al. Pancreatic cancer. J Am Coll Surg 1998 187 : 429 442.
3. American Gastroenterology Association. Technical review on epidemiology, diagnosis and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 1999 117 : 1463 1484.
4. Li D, Xie K, Wolff R et al. Pancreatic cancer. Lancet 2004 363 : 1049 1057.
5. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Eng J Med 2004 350 : 1200 1210.
6. Pino SM, Xiong HQ, Mcconkey D et al. Novel therapies for pancreatic adenocarcinoma. Curr Gastroenterol Rep 2004 6 : 119 125.
7. Jones HA, Hahn SM, Bernhard E et al. Ras inhibitors and radiation therapy. Semin Radiat Oncol. 2001 11 : 328 337.
8. Westphal S, Kalthoff H. Apoptosis: targets in pancreatic cancer. Mol Cancer 2003 2 : 6.
9. Visconti R, Grieco D. New insights on oxidative stress in cancer. Curr Opin Drug Discov Devel 2009 12 : 240 245.
10. Ruiz-Rabelo JF, Vazquez R, Perea MD et al. Beneficial properties of melatonin in an experimental model of pancreatic cancer. J Pineal Res 2007 43 : 270 275.
11. Rosen J, Than NN, Koch DK et al. Interactions of melatonin and its metabolites with the ABTS cation radical: extension of the radical scavenger cascade and formation of a novel class of oxidation products, C2-substituted 3-indolinones. J Pineal Res 2006 41 : 374 381.
12. Tan DX, Manchester LC, Terron MP et al. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007 42 : 28 42.
13. Peyrot F, Ducrocq C. Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species. J Pineal Res 2008 45 : 235 246.
14. Hardeland R, Tan DX, Reiter RJ. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 2009 47 : 109 126.
15. Reiter RJ. Mechanisms of cancer inhibition by melatonin. J Pineal Res 2004 37 : 213 214.
16. Bejarano I, Redondo PC, Espino J et al. Melatonin induces mitochondrial-mediated apoptosis in human myeloid HL-60 cells. J Pineal Res 2009 46 : 392 400.
17. 3 in cultured cancer cells. J Pineal Res 2008 44 : 121 126.
18. Furukawa F, Nishikawa A, Lee IS et al. A cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation phase of N-nitrosobis(2-oxopropyl)amine- induced pancreatic carcinogenesis in hamsters. Int J Cancer 2003 104 : 269 273.
19. Yip-Schneider MT, Wu H, Njoku V et al. Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer. Pancreas 2008 37 : 45 53.
20. Pour P, Althoff J, Kruger FW et al. A potent pancreatic carcinogen in Syrian golden hamster: N-nitroso-bis(2-oxopropyl)amine. J Natl Cancer Inst 1977 58 : 1449 1453.
21. Reddy BS, Hirose Y, Lubet R et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000 60 : 293 297.
22. Kawamori T, Rao CV, Seibert K et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase 2 inhibitor, against colon carcinogenesis. Cancer Res 1998 58 : 40941 40942.
23. Harris RE, Alshafie GA, Abou-Issa H et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000 60 : 2101 2103.
24. Kubatka P, Kalicka K, Chamilova M et al. Nimesulide and melatonin in mammary carcinogenesis prevention in female sprague-dawley rats. Neoplasma 2002 49 : 255 259.
25. Takahashi M, Furukawa F, Toyoda K et al. Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters faster initiation with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis 1990 11 : 393 395.
26. Meijers M, Van Garderen-Hoetmer A, Lamers CB et al. Role of cholecystokinin in the development of BOP-induced pancreatic lesions in hamsters. Carcinogenesis 1990 11 : 2223 2226.
27. Hissin PJ, Hilf R. A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 1976 74 : 214 226.
28. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem 1988 34 : 479 500.
29. Aebi H. Catalase in vitro. Meth Enzymol 1984 105 : 121 126.
30. Flohé L, Gunzler WA. Assays of glutathione peroxidase. Meth Enzymol 1984 105 : 114 121.
31. Benz CC, Yau C. Ageing, oxidative stress and cancer: paradigms in parallax. Nat Rev Cancer 2008 8 : 875 879.
32. Gingell R, Wallcave L, Nagel D et al. Metabolism of the pancreatic carcinogens N-nitroso-bis(2-oxopropyl)amine and N-nitroso-bis(2-hydroxypropyl) amine in the Syrian hamster. J Natl Cancer Inst 1976 57 : 1175 1178.
33. Wenger FA, Kilian M, Ridders J et al. Influence of antioxidative vitamins A, C and E on lipid peroxidation in BOP induced pancreatic cancer in Syrian hamsters. Prostagland Leukot Fatty Acids 2001 65 : 165 171.
34. Wenger FA, Kilian M, Jacobi CA et al. Effects of octreotide on liver metastasis and intrametastatic lipid peroxidation in experimental pancreatic cancer. Oncology 2001 60 : 282 288.
35. Woutersen RA, Appel MJ, Van Garderen-Hoetmer A. Modulation of pancreatic carcinogenesis by antioxidants. Food Chem Toxicol 1999 37 : 981 984.
36. Hayes CJ, Whittaker BP, Watson SA et al. Synthesis and preliminary anticancer activity studies of C4 and C8-modified derivatives of catechin gallate (CG) and epicatechin gallate (ECG). J Org Chem 2006 71 : 9701 9712.
37. Rodriguez C, Mayo JC, Sainz RM et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004 36 : 1 9.
38. Pawlikowski M, Winczyk K, Karasek M. Oncostatic action of melatonin: facts and question marks. Neuro Endocrinol Lett 2002 23 : 24 29.
39. Konkmaz A, Tamura H, Manchester LC et al. Combination of melatonin and a peroxisome proliferator-activated receptor-γ agonist induces apoptosis in a breast cancer cell line. J Pineal Res 2009 46 : 115 116.
40. Carrillo-Vico A, Guerrero JM, Lardone PJ et al. A review of the multiple actions of melatonin on the immune system. Endocrine 2005 27 : 189 200.
41. Park JW, Hwang MS, Suh SI, Baek WK. Melatonin down regulates HIF-1α expression through inhibition of protein translation in prostate cancer cells. J Pineal Res 2009 46 : 415 421.
42. Bartsch C, Bartsch H. Melatonin in cancer patients and in tumor-bearing animals. Adv Exp Med Biol 1999 467 : 247 264.
43. Anisimov VN, Alimova IN, Baturin DA et al. The effect of melatonin treatment regimen on mammary adenocarcinoma development in HER-2/neu transgenic mice. Int J Cancer 2003 103 : 300 305.
44. Yip-Schneider MT, Barnard DS, Billings SD et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000 21 : 139 146.
45. Hasan S, Satake M, Dawson DW et al. Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers. Pancreas 2008 37 : 121 127.
46. Nagahara T, Okano J, Murawaki Y. Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase-2-inhibitor on liver metastasis on human cancer cell. Oncol Rep 2007 18 : 1281 1290.
47. Ohno S, Ohno Y, Suzuki N et al. Cyclooxygenase-2-expression correlates with apoptosis and angiogenesis in endometrial cancer tissue. Anticancer Res 2007 100 : 515 519.
48. Matsubayashi H, Infante JR, Winter J et al. Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol Ther 2007 6 : 1569 1575.
49. Hu PJ, Yu J, Zeng ZR et al. Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004 53 : 195 200.
50. De Heer P, Sandel MH, Guertens G et al. Celecoxib inhibit growth of tumors in a syngeneic rat liver metastases model for colorectal cancer. Cancer Chemother Pharmacol 2008 62 : 811 819.